Pfizer’s Growing Hematology Pipeline Matures With New Hemophilia, Sickle Cell Data
Multiple Modalities Advance Across Non-Malignant Diseases
The big pharma is building on its hematology legacy beyond coagulation factors with marstacimab and gene therapies for hemophilia, plus oral and injectable medicines for sickle cell disease.
